News
05-09-2011, 10:11 PM
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.
More... (http://www.news-medical.net/news/20110510/Acceleron-presents-RAP-661-preclinical-data-in-osteopenic-mice-at-International-meeting.aspx)
More... (http://www.news-medical.net/news/20110510/Acceleron-presents-RAP-661-preclinical-data-in-osteopenic-mice-at-International-meeting.aspx)